Alzheimer's disease genetics: current knowledge and future challenges
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is highly heritable, but genetically complex. Recently, three large‐scale genome‐wide association studies have made substantial breakthroughs in disentangling the genetic architecture of the disease. These studies combined include data from over 43 000 independent individuals and provide compelling evidence that variants in four novel susceptibility genes (CLU, PICALM, CR1, BIN1) are associated with disease risk. These findings are tremendously exciting, not only in providing new avenues for exploration, but also highlighting the potential for further gene discovery when larger samples are analysed. Here we discuss progress to date in identifying risk genes for dementia, ways forward and how current findings are refining previous ideas and defining new putative primary disease mechanisms. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 16×
“Genetic variation in the APP, PSEN1 and PSEN2 genes has little or no effect on susceptibility to late-onset AD (Bertram et al., 2007; Harold et al., 2009), suggesting a degree of aetiological heterogeneity.”
InfluentialSelf-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Wellcome Trust Case Control Consortium, Zeggini, E., Scott, L. J., Saxena, R., Voight, B. F., Marchini, J. L., Hu, T., de Bakker, P. I., Abecasis, G. R., Almgren, P., et al. (2008) · Nature Genetics · doi:10.1038/ng.120 · Cited by 1,864
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 3×
“Compared to those with no e4 alleles, the increased risk for AD is two-to-four fold in those with one e4 allele and about 12-fold in e4 homozygotes (Farrer et al., 1997; Bertram et al., 2007).”
BackgroundTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 1×
“Alzheimer’s disease (AD) is themost common formofdementiawith heritability estimates as high as 79% (Gatz et al., 2006).”
BackgroundThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 2×
“However, prevailing evidence suggests that the differential effects of ApoE isoforms on Ab aggregation and clearance play a major role in AD pathogenesis (Kim et al., 2009).”
BackgroundSchmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Genetic Mapping in Human Disease
Altshuler, D., Daly, M. J., & Lander, E. S. (2008) · Science · doi:10.1126/science.1156409 · Cited by 1,452 · cited 2×
“…date more than 400 GWA studies have been published (Hindorff et al., 2010), identifying over 250 common genetic variants that show replicated association with polygenic traits (Altshuler et al., 2008; Lettre and Rioux, 2008; Mohlke et al., 2008; Hirschhorn and Lettre, 2009; Hindorff et al., 2010).”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“Epidemiological studies have shown that long-term use of anti-inflammatory drugs reduces the risk for AD and Parkinson’s disease (McGeer et al., 1996; Chen et al., 2005; Vlad et al., 2008).”
BackgroundStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363 · cited 3×
“Until recently the Apolipoprotein gene (APOE) was the only unequivocally established susceptibility gene for LOAD (Corder et al., 1993; Saunders et al., 1993; Schmechel et al., 1993; Strittmatter et al., 1993).”
BackgroundGenome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Brain Cholesterol: Long Secret Life Behind a Barrier
Björkhem, I., & Meaney, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000120374.59826.1b · Cited by 1,044 · cited 1×
“Lipids are abundant in the brain and most are generated in the glial cells and transported to neurons (Bjorkhem and Meaney, 2004).”
BackgroundA HapMap harvest of insights into the genetics of common disease
Manolio, T. A., Brooks, L. D., & Collins, F. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34772 · Cited by 889 · cited 2×
“5 (Manolio et al., 2008) and even in combination explain only a small proportion of heritability to complex traits (Manolio et al.”
BackgroundInfluentialCampion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785 · cited 1×
“Early-onset familial AD accounts for less than 1% of all AD cases (Campion et al., 1999).”
BackgroundapoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 2×
“Ab can be cleared across the blood brain barrier through interactions with lipoprotein receptors and the different ApoE isoforms interact preferentially with different receptors (Deane et al., 2008) such that apo e4 bound lipoprotein particles export Ab less efficiently than e2- or e3bound particles (Bates et al.”
BackgroundAltered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720
Estimation of significance thresholds for genomewide association scans
Dudbridge, F., & Gusnanto, A. (2008) · Genetic Epidemiology · doi:10.1002/gepi.20297 · Cited by 703 · cited 2×
“Given the number of hypotheses being tested simultaneously a P-value below 5.0 10 8 is usually required to declare a locus genomewide significant (Dudbridge and Gusnanto, 2008; Moskvina and Schmidt, 2008).”
BackgroundInfluentialBell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 1×
“…e ta k e ac co u n t o f st ra ti fi ca ti o n is su es th at w er e co n tr o ll ed fo r in th e es ti m at io n o f th e O R in ea ch o f th e in d iv id u al st u d ie s. Copyright # 2010 John Wiley & Sons, Ltd. Int J Geriatr Psychiatry 2011; 26: 793–802. blood–brain barrier (Bell et al., 2007).”
BackgroundProtective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535 · cited 1×
“Epidemiological studies have shown that long-term use of anti-inflammatory drugs reduces the risk for AD and Parkinson’s disease (McGeer et al., 1996; Chen et al., 2005; Vlad et al., 2008).”
BackgroundBertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M. F., Schjeide, B. M. M., Hooli, B., DiVito, J., Ionita, I., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.10.008 · Cited by 511 · cited 5×
“Most notably they have identified SNPs within TNK1 (Grupe et al., 2007), GAB2 (Reiman et al., 2007), GOLM1 (Li et al., 2008), CD33 (Bertram et al., 2008), ATXN1 (Bertram et al., 2008), FAM113B (Beecham et al., 2009), DISC1 (Beecham et al., 2009), ZNF224 (Beecham et al., 2009), PCDH11X (Carrasquillo et al., 2009) and T…”
InfluentialCandidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
Li, H., Wetten, S., Li, L., St. Jean, P. L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M. R., Briley, J. D., Borrie, M., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.3 · Cited by 499 · cited 3×
“Most notably they have identified SNPs within TNK1 (Grupe et al., 2007), GAB2 (Reiman et al., 2007), GOLM1 (Li et al., 2008), CD33 (Bertram et al., 2008), ATXN1 (Bertram et al., 2008), FAM113B (Beecham et al., 2009), DISC1 (Beecham et al., 2009), ZNF224 (Beecham et al., 2009), PCDH11X (Carrasquillo et al., 2009) and T…”
Self-citationJones, S. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00155-8 · Cited by 488
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · cited 1×
“Clusterin has also been shown to have a role in the Ab clearance (DeMattos et al., 2004) and its role in lipid trafficking that is parallel to that of ApoE could be pertinent to Ab clearance (Jenne et al., 1991; Calero et al., 2000).”
Potkin, S. G., Guffanti, G., Lakatos, A., Turner, J. A., Kruggel, F., Fallon, J. H., Saykin, A. J., Orro, A., Lupoli, S., Salvi, E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006501 · Cited by 376 · cited 1×
“Disease Neuroimaging Initiative (ADNI) GWA study (Potkin et al., 2009), which supplemented a traditional case–control GWA study with analysis of hippocampal grey matter density as a quantitative trait.”
BackgroundTebar, F., Bohlander, S. K., & Sorkin, A. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.8.2687 · Cited by 320
Autoimmune diseases: insights from genome-wide association studies
Lettre, G., & Rioux, J. D. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn246 · Cited by 317
Dreyling, M. H., Martinez-Climent, J. A., Zheng, M., Mao, J., Rowley, J. D., & Bohlander, S. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4804 · Cited by 310
Liang, W. S., Dunckley, T., Beach, T. G., Grover, A., Mastroeni, D., Ramsey, K., Caselli, R. J., Kukull, W. A., McKeel, D., Morris, J. C., et al. (2008) · Physiological Genomics · doi:10.1152/physiolgenomics.00242.2007 · Cited by 309 · cited 1×
“In individuals with AD, CLU expression is increased in affected cortical areas of the brain and like APOE, is present in amyloid plaques and in the cerebrospinal fluid (McGeer et al., 1992; Giannakopoulos et al., 1998; Calero et al., 2000; Liang et al., 2008).”
BackgroundWeisgraber, K. H. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42621-5 · Cited by 304
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease
Carrasquillo, M. M., Zou, F., Pankratz, V. S., Wilcox, S. L., Ma, L., Walker, L. P., Younkin, S. G., Younkin, C. S., Younkin, L. H., Bisceglio, G. D., et al. (2009) · Nature Genetics · doi:10.1038/ng.305 · Cited by 296 · cited 3×
“Most notably they have identified SNPs within TNK1 (Grupe et al., 2007), GAB2 (Reiman et al., 2007), GOLM1 (Li et al., 2008), CD33 (Bertram et al., 2008), ATXN1 (Bertram et al., 2008), FAM113B (Beecham et al., 2009), DISC1 (Beecham et al., 2009), ZNF224 (Beecham et al., 2009), PCDH11X (Carrasquillo et al., 2009) and T…”
Genome-wide Association Study Implicates a Chromosome 12 Risk Locus for Late-Onset Alzheimer Disease
Beecham, G. W., Martin, E. R., Li, Y.-J., Slifer, M. A., Gilbert, J. R., Haines, J. L., & Pericak-Vance, M. A. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.12.008 · Cited by 260
Genome-wide association studies in Alzheimer’s disease
Bertram, L., & Tanzi, R. E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp406 · Cited by 257
AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling
Pant, S., Sharma, M., Patel, K., Caplan, S., Carr, C. M., & Grant, B. D. (2009) · Nature Cell Biology · doi:10.1038/ncb1986 · Cited by 218
Gong, J.-S., Kobayashi, M., Hayashi, H., Zou, K., Sawamura, N., Fujita, S. C., Yanagisawa, K., & Michikawa, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203934200 · Cited by 214 · cited 1×
“ApoE e4 does not operate as efficiently in delivery of cholesterol to neurons as ApoE e3 (Gong et al., 2002) and the different isoforms bind to different populations of lipoproteins (Weisgraber, 1990).”
BackgroundDistribution of clusterin in Alzheimer brain tissue
McGeer, P. L., Kawamata, T., & Walker, D. G. (1992) · Brain Research · doi:10.1016/0006-8993(92)90071-g · Cited by 212 · cited 1×
“In individuals with AD, CLU expression is increased in affected cortical areas of the brain and like APOE, is present in amyloid plaques and in the cerebrospinal fluid (McGeer et al., 1992; Giannakopoulos et al., 1998; Calero et al., 2000; Liang et al., 2008).”
BackgroundPericak-Vance, M. A. (1997) · JAMA · doi:10.1001/jama.1997.03550150041033 · Cited by 206
Apolipoprotein E4 Forms a Molten Globule
Morrow, J. A., Hatters, D. M., Lu, B., Höchtl, P., Oberg, K. A., Rupp, B., & Weisgraber, K. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204898200 · Cited by 204 · cited 1×
“ApoE e4 is a more unstable protein than ApoE e3 or ApoE e2 (Morrow et al., 2002).”
BackgroundA genome-wide association study for late-onset Alzheimer's disease using DNA pooling
Abraham, R., Moskvina, V., Sims, R., Hollingworth, P., Morgan, A., Georgieva, L., Dowzell, K., Cichon, S., Hillmer, A. M., O'Donovan, M. C., et al. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-44 · Cited by 195
Self-citationEvidence for CALM in Directing VAMP2 Trafficking
Harel, A., Wu, F., Mattson, M. P., Morris, C. M., & Yao, P. J. (2008) · Traffic · doi:10.1111/j.1600-0854.2007.00694.x · Cited by 144 · cited 1×
“This process is crucial to neuronal function and memory formation (Harel et al., 2008).”
BackgroundGenetics of Alzheimer's disease: recent advances
Avramopoulos, D. (2009) · Genome Medicine · doi:10.1186/gm34 · Cited by 136
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124 · cited 1×
“Compared to those with no e4 alleles, the increased risk for AD is two-to-four fold in those with one e4 allele and about 12-fold in e4 homozygotes (Farrer et al., 1997; Bertram et al., 2007).”
BackgroundGiannakopoulos, P., Kövari, E., French, L. E., Viard, I., Hof, P. R., & Bouras, C. (1998) · Acta Neuropathologica · doi:10.1007/s004010050815 · Cited by 90 · cited 1×
“In individuals with AD, CLU expression is increased in affected cortical areas of the brain and like APOE, is present in amyloid plaques and in the cerebrospinal fluid (McGeer et al., 1992; Giannakopoulos et al., 1998; Calero et al., 2000; Liang et al., 2008).”
BackgroundKirszbaum, L., Bozas, S. E., & Walker, I. D. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80330-j · Cited by 76 · cited 2×
“CLU is an important inhibitor of complement activation, modulating the membrane attack complex (Kirszbaum et al., 1992), and it has been suggested that it acts to prevent the inflammatory response associated with complement activation downstream of protein aggregation (e.g., Ab accumulation).”
BackgroundSynaptic distribution of the endocytic accessory proteins AP180 and CALM
Yao, P. J., Petralia, R. S., Bushlin, I., Wang, Y., & Furukawa, K. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20362 · Cited by 49
Cited by
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570
Neuroprotective Effects of Quercetin in Alzheimer’s Disease
Khan, H., Ullah, H., Aschner, M., Cheang, W. S., & Akkol, E. K. (2019) · Biomolecules · doi:10.3390/biom10010059 · Cited by 537
An early and late peak in microglial activation in Alzheimer’s disease trajectory
Fan, Z., Brooks, D. J., Okello, A., & Edison, P. (2017) · Brain · doi:10.1093/brain/aww349 · Cited by 424
Revett, T. J., Baker, G. B., Jhamandas, J., & Kar, S. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110190 · Cited by 292
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Metadata
- Authors
- Hollingworth, P., Harold, D., Jones, L., Owen, M. J., & Williams, J.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2010-10-19
- Volume
- 26
- Issue
- 8
- Pages
- 793-802
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W2046599479
- Cited by
- 102
- References
- 49
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.